Barclays PLC boosted its position in shares of Evolus, Inc. (NASDAQ:EOLS - Free Report) by 268.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 93,662 shares of the company's stock after acquiring an additional 68,213 shares during the period. Barclays PLC owned 0.15% of Evolus worth $1,518,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also bought and sold shares of EOLS. Armistice Capital LLC purchased a new position in shares of Evolus during the 2nd quarter valued at $3,906,000. Charles Schwab Investment Management Inc. boosted its stake in Evolus by 173.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 418,576 shares of the company's stock worth $6,781,000 after buying an additional 265,635 shares in the last quarter. Ikarian Capital LLC bought a new position in Evolus during the third quarter valued at approximately $4,184,000. Walleye Capital LLC purchased a new position in shares of Evolus during the third quarter worth approximately $3,438,000. Finally, Healthcare of Ontario Pension Plan Trust Fund bought a new stake in shares of Evolus in the 2nd quarter worth approximately $1,326,000. Institutional investors own 90.69% of the company's stock.
Evolus Trading Up 2.4 %
NASDAQ EOLS opened at $10.24 on Monday. The stock's fifty day moving average price is $12.24 and its 200-day moving average price is $13.76. The stock has a market cap of $648.41 million, a P/E ratio of -11.25 and a beta of 1.32. Evolus, Inc. has a 12 month low of $9.84 and a 12 month high of $17.82. The company has a current ratio of 2.47, a quick ratio of 2.23 and a debt-to-equity ratio of 20.58.
Wall Street Analysts Forecast Growth
A number of brokerages recently commented on EOLS. Cantor Fitzgerald reiterated an "overweight" rating on shares of Evolus in a research report on Monday, September 16th. HC Wainwright restated a "buy" rating and issued a $27.00 price objective on shares of Evolus in a report on Thursday, November 7th.
View Our Latest Stock Report on EOLS
Evolus Profile
(
Free Report)
Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.
Further Reading
Before you consider Evolus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evolus wasn't on the list.
While Evolus currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
